Scientists have identified an enzyme that promotes cell proliferation in the most common and lethal ovarian cancer and could serve as a treatment target.
Updated: 07/16/2019 12:03P
Vivek Ramaswamys fast-growing biotech group is paying $10 million upfront for rights to SAL200 (Tonabacase), a biologic it says is based on an enzyme (endolysin) derived from a bacteriophage—a virus that infects bacteria—that acts by breaking down ...
Updated: 11/20/2018 09:41A